IMO, what we have potentially is a mess, and those attempting to decorate the situation putting little rainbows and stars around it aka short term turbulance but longer term “cure” — a CROC. Big Pharma in the mix, IMO, and short term or longer term, same difference, common shareholders best interests not in play, never have been, old gang or new gang, however you choose to look at it.
In the meanwhile, as one poster wrote, “This was an undisciplined knee jerk reaction from the BOD”, and would add hostile, to take control of company, resulting in trading halt for couple days, RMTI back in a court of law with legal costs to the company, hence, the shareholders, and an ongoing legal dispute, non-trivial by any measure, with outcome uncertain.
Competitors watching the “show” (they know what’s going on) along with the rest of the industry — CMS watching. Time of essence, the renal/iron deficiency space moving forward rapidly, providers waiting, patients waiting, meanwhile, a potential mess in the cards — IMO, all in the name of “a plan”, by “a plan”, for “a plan”, put in motion a while ago, so goes hypothetical.
Chioini, yes, self-serving bastad, but, IMO, the alternative is not “peaches and cream” either. What is the company and shareholders REALLY gaining from all this? Can anyone answer this question? Chioini/Klema terminated is not a viable answer, IMO. Why? — because,IMO, if Big Pharma wants the company and its technology then get the BOD and majority shareholders aligned (which are aligned anyway) and buy the damn thing for a reasonsble price, it’s not like the funds are not available. Why the hostility to take control of the company (IMO) as a prelude — what, a few T’s to cross and I’s to dot prior to end-game have we?
ALL above, in my opinion
